Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model

International Journal of Antimicrobial Agents

Volumn 29, Issue 2, 2007, Pages 165-169

  Smirnova, Maria V ^a   Lubenko, Irene Yu ^a,b   Portnoy, Yury A ^a   Zinner, Stephen H ^c   Firsov, Alexander A ^a  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b P K ANOKHIN INSTITUTE OF NORMAL PHYSIOLOGY   (Russian Federation)

^c MOUNT AUBURN HOSPITAL   (United States)

Author keywords

Daptomycin; Effect endpoints; In vitro models; Pharmacodynamics; Staphylococcus aureus; Vancomycin

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DRUG EFFECT; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 33846081133     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.09.011     Document Type: Article

References (20)

1. Firsov A.A., Lubenko I.Y., Portnoy Y.A., Zinner S.H., and Vostrov S.N. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob Agents Chemother 45 (2001) 927-931
2. Firsov A.A., Vostrov S.N., Shevchenko A.A., and Cornaglia G. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother 41 (1997) 1281-1287
3. Firsov A.A., and Zinner S.H. Use of modeling techniques to aid in antibiotic selection. Curr Infect Dis Rep 3 (2001) 35-43
4. E over other integral parameters. Chemotherapy 48 (2002) 275-279
5. Firsov A.A., Zinner S.H., Vostrov S.N., Portnoy Y.A., and Lubenko I.Y. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother 50 (2002) 533-539
6. Stratton CW, Liu C, Weeks LS. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies. Antimicrob Agents Chemother 1987;31:121-15.
7. 2+ and albumin on these drugs. Antimicrob Agents Chemother 35;1991:121-15.
8. Dvorchik B.H., Brazier D., Debruin M.F., and Arbeit R.D. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 47 (2003) 1318-1323
9. Woodworth J.R., Nyhart Jr. E.H., Brier G.L., Wolny J.D., and Black H.R. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 36 (1992) 318-325
10. Winter M.E. Vancomycin. In: Koda-Kimble M.A., and Young L.Y. (Eds). Basic clinical pharmacokinetics. 2nd ed. (1988), Applied Therapeutics, Inc., Vancouver, Washington
11. Firsov A.A., Shevchenko A.A., Vostrov S.N., and Zinner S.H. Inter- and intraquinolone predictors of antimicrobial effect in an in-vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother 42 (1998) 659-665
12. Firsov A.A., Savarino D., Ruble M., et al. Predictors of effect of ampicillin-sulbactam against TEM-1 β-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob Agents Chemother 40 (1996) 734-738
13. Firsov A.A., Chernykh V.M., and Navashin S.M. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrob Agents Chemother 34 (1991) 12-17
14. Akins R.A., and Rybak M.J. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamycin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 44 (2000) 1925-1929
15. Akins R.L., and Rybak M.J. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 45 (2001) 454-459
16. Cha R., Brown W.J., and Rybak M.J. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 47 (2003) 3960-3963
17. Cha R., Grucz JrRG, and Rybak M.J. Daptomycin dose-effect relationship against resistant Gram-positive organisms. Antimicrob Agents Chemother 47 (2003) 1598-1603
18. Cha R., and Rybak M.J. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 47 (2003) 539-546
19. Rybak M.J., Hershberger E., Moldovan T., and Grucz R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, include vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 44 (2000) 1062-1066
20. Tsuji B.T., and Rybak M.J. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 49 (2005) 2735-2745